文献速递炎症性肠病

炎症性肠病患者远程医疗的随机对照试验(TELE-IBD)

A Randomized Controlled Trial of TELEmedicine for Patients with Inflammatory Bowel Disease (TELE-IBD).
PubMed 文献 · Am J Gastroenterol · 2019-01-01

本研究将过去2年症状加重的炎症性肠病患者随机分为远程医疗组(每两周或每周短信监测)或标准治疗组,比较1年内疾病活动度和生活质量变化。共纳入348例,各组疾病活动度和生活质量均有改善,但组间未达显著差异;远程医疗组住院减少,非侵入性诊断检查、电话和电子接触增加。

要点

  • 远程医疗组与标准治疗组在疾病活动度和生活质量变化上无显著差异
  • 远程医疗组非IBD相关住院减少,但非侵入性诊断检查、电话和电子接触增加
  • 每周远程医疗组较对照组IBD相关住院更少,非侵入性诊断检查和电子接触更多

核心结论

  • 所有参与者疾病活动度和生活质量均有改善,但使用TELE-IBD系统未进一步改善。
  • TELE-IBD参与者住院减少,同时非侵入性诊断检查、电话和电子接触增加。
  • 需要研究确定TELE-IBD能否通过患者参与得到改进,以及能否通过替代标准治疗来降低医疗资源利用。

研究设计与样本

  • 1年随机对照试验,纳入过去2年症状加重的炎症性肠病患者。
  • 共纳入348例参与者(对照组117例、TELE-IBD每两周组115例、TELE-IBD每周组116例),259例(74.4%)完成研究。
  • 年龄38.9±12.3岁,56.6%为女性,91.9%为白人,67.9%为克罗恩病,42.5%基线时有活动性疾病。

主要发现

  • 克罗恩病中,所有组疾病活动度均下降(对照组-5.2±5.0至3.7±3.6,TELE-IBD每两周组4.7±4.1至4.2±3.9,TELE-IBD每周组4.2±4.2至3.2±3.4,各组p<0.0001)。
  • 溃疡性结肠炎中,仅对照组疾病活动度显著下降(对照组2.9±3.1至1.4±1.4,p=0.01;TELE-IBD每两周组2.7±3.1至1.7±1.9,p=0.35;TELE-IBD每周组2.5±2.5至2.0±1.8,p=0.31)。
  • 所有组生活质量均提高,仅TELE-IBD每两周组显著(对照组168.1±34.0至179.3±28.2,p=0.06;TELE-IBD每两周组172.3±33.1至181.5±28.2,p=0.03;TELE-IBD每周组172.3±34.5至179.2±32.8,p=0.10)。
  • 未调整和调整后的疾病活动度和生活质量变化在各组间无显著差异。
  • 所有组医疗资源利用均增加;与对照组相比,TELE-IBD每周组IBD相关住院更少,非侵入性诊断检查和电子接触更多;两个TELE-IBD组非IBD相关住院减少,电话增加。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 需要研究确定TELE-IBD能否通过患者参与得到改进,以及能否通过替代标准治疗来降低医疗资源利用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Telemedicine has shown promise in inflammatory bowel disease (IBD). The objective of this study was to compare disease activity and quality of life (QoL) in a 1-year randomized trial of IBD patients receiving telemedicine vs. standard care. METHODS: Patients with worsening symptoms in the prior 2 years were eligible for randomization to telemedicine (monitoring via texts EOW or weekly) or standard care. The primary outcomes were the differences in change in disease activity and QoL between the groups; change in healthcare utilization among groups was a secondary aim. RESULTS: 348 participants were enrolled (117 control group, 115 TELE-IBD EOW, and 116 TELE-IBD weekly). 259 (74.4%) completed the study. Age was 38.9 ± 12.3 years, 56.6% were women, 91.9% were Caucasian, 67.9% had Crohn's disease (CD) and 42.5% had active disease at baseline. In CD, all groups experienced a decrease in disease activity (control -5.2 ± 5.0 to 3.7 ± 3.6, TELE-IBD EOW 4.7 ± 4.1 to 4.2 ± 3.9, and TELE-IBD weekly 4.2 ± 4.2 to 3.2 ± 3.4, p < 0.0001 for each of the groups) In UC, only controls had a significant decrease in disease activity (control 2.9 ± 3.1 to 1.4 ± 1.4, p = 0.01, TELE-IBD EOW 2.7 ± 3.1 to 1.7 ± 1.9, p = 0.35, and TELE-IBD Weekly 2.5 ± 2.5 to 2.0 ± 1.8, p = 0.31). QoL increased in all groups; the increase was significant only in TELE-IBD EOW (control 168.1 ± 34.0 to 179.3 ± 28.2, p = 0.06, TELE-IBD EOW 172.3 ± 33.1 to 181.5 ± 28.2, p = 0.03, and TELE-IBD Weekly 172.3 ± 34.5 to 179.2 ± 32.8, p = 0.10). Unadjusted and adjusted changes in disease activity and QoL were not significantly different among groups. Healthcare utilization increased in all groups. TELE-IBD weekly were less likely to have IBD-related hospitalizations and more likely to have non-invasive diagnostic tests and electronic encounters compared to controls; both TELE-IBD groups had decreased non-IBD related hospitalizations and increased telephone calls compared to controls. DISCUSSION: Disease activity and QoL, although improved in all participants, were not improved further through use of the TELE-IBD system. TELE-IBD participants experienced a decrease in hospitalizations with an associated increase in non-invasive diagnostic tests, telephone calls and electronic encounters. Research is needed to determine if TELE-IBD can be improved through patient engagement and whether it can decrease healthcare utilization by replacing standard care.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Cross RK, Langenberg P, Regueiro M, et al. A Randomized Controlled Trial of TELEmedicine for Patients with Inflammatory Bowel Disease (TELE-IBD). Am J Gastroenterol. 2019. PMID: 30410041. doi:10.1038/s41395-018-0272-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。